mesothelioma

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development. It is an enzyme that deacetylates lysine residues on the N-terminal of the core histones.

ODQ is an effective and selective soluble guanylyl cyclase (sGC) inhibitor.

K-975 is a highly selective, orally active TEAD inhibitor, effectively inhibiting protein-protein interactions between TEAD and YAP1/TAZ.

Dihydro-5-azacytidine FA (DHAC) is a pyrimidine analog that has antitumor activity, inhibits cell growth, inhibits DNA methylation, and may be used in the study of malignant mesothelioma.

Pemetrexed disodium (LY-231514) is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesothelioma. Pemetrexed disodium therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury.

Pemetrexed disodium heptahydrate (LY231514) is an antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinyl-adenosine 5'-monophosphate (GARMT) with K_i values of 1.3 nM, 7.2 nM, and 65 nM respectively. This inhibits the formation of precursor purine and pyrimidine nucleotides and cancer cell proliferation, making it suitable for research into pleural mesothelioma and non-small cell lung cancer (NSCLC).

(E)-KPT330 is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells.

NR6 is an innovative and potent ALDH1A3 inhibitor with high selectivity. It effectively suppresses the growth of mesothelioma multicellular spheroids and the recruitment of neutrophils.

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance the activities of PP2A and PTP1B in malignant pleural mesothelioma cells. Additionally, 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis in NCI-H28 malignant pleural mesothelioma cells.

TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.

Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor with anti-tumor properties. It inhibits FAK autophosphorylation in prostate cancer cells and suppresses spheroid formation and in situ tumor growth in vivo. Ifebemtinib (tosylate) is applicable in cancer research, including studies on solid tumors, breast cancer, and malignant pleural mesothelioma.

Pemetrexed tromethamine is a chemotherapy drug used for pleural mesothelioma and non-small cell lung cancer.

JY-1-106 is a BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.

MYF-03-176 is an orally active TEAD1/3/4 inhibitor with IC₅₀ values of 47/32/71 nM, respectively. It also inhibits TEAD transcriptional activity and cell growth in NCI-H226 cells, exhibiting antitumour activity in malignant pleural mesothelioma (MPM) cells with defective Hippo signalling and in mouse xenograft models.

MYF-03-69 (TEAD-IN-3) is a covalent and irreversible pan-TEAD inhibitor with IC₅₀ values of 385/143/558/173 nM for TEAD1/TEAD2/TEAD3/TEAD4, respectively. MYF-03-69 inhibits TEAD transcriptional activity (IC₅₀ = 56 nM), upregulates the pro-apoptotic gene BMF, and suppresses mesothelioma cancer cells with defective Hippo signaling, making it suitable for malignant pleural mesothelioma (MPM).

VT101 is a TEAD Auto-palmitoylation inhibitor that Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. VT101 inhibited the firefly luciferase reporter dose-dependently and had no 204 effect on the Renilla luciferase reporter.

VT-102 is a TEAD Auto-palmitoylation inhibitor that Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. VT102 inhibited the firefly luciferase reporter dose-dependently and had no 204 effect on the Renilla luciferase reporter.

Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).

Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-activated molecule coupling, Anetumab ravtansine.Anetumab can be used to study the treatment of metastatic pleural mesothelioma.

Anti-Mesothelin Antibody (such as Amatuximab/MORAb-009) is a chimeric monoclonal antibody targeting mesothelin (MSLN). Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is overexpressed in various malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, while exhibiting restricted expression in normal tissues. The antibody binds to mesothelin with high affinity, and its mechanisms of action primarily include: 1. Blocking the interaction between mesothelin and MUC16 (CA125), thereby inhibiting tumor cell adhesion and metastasis; 2. Inducing direct tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). In basic research, it is widely utilized to evaluate the therapeutic efficacy of targeting mesothelin and for the development of antibody-drug conjugates (ADCs).

Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) that specifically targets MSLN. It is applicable in research on ovarian cancer, mesothelioma, and pancreatic cancer.

YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. It induces CD26 nuclear translocation via the caveolin pathway and inhibits tumor cell proliferation by delaying the G2/M cell cycle transition. Additionally, YS110 blocks the binding of MERS CoV S1 to CD26, thereby preventing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This compound is applicable in research on cancer and infections, including malignant mesothelioma and MERS.